Disease · HP_0004324
Increased body weight
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Increased body weight. Diseases, record HP_0004324. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0004324
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Increased body weight
- Open Targets ID
- HP_0004324
- Highest stage of its drugs
- Phase 3, for 12 of its 26 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs26
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ASCORBIC ACID | CHEMBL196 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| CAGRILINTIDE | CHEMBL4802169 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DAPAGLIFLOZIN | CHEMBL429910 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EZETIMIBE | CHEMBL1138 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OLANZAPINE | CHEMBL715 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OMEGA-3 FATTY ACIDS | CHEMBL4298065 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| PITAVASTATIN | CHEMBL1201753 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ROSUVASTATIN | CHEMBL1496 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 26
See all 26 drugsTargets71
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| HTR2C | 5-hydroxytryptamine receptor 2C | 3 | Serotonin 2c (5-HT2c) receptor agonist; Serotonin 2c (5-HT2c) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3358 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | D2-like dopamine receptor antagonist; Dopamine D2 receptor partial agonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 2 | Glucagon-like peptide 1 receptor agonist | Phase 3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| HTR2A | 5-hydroxytryptamine receptor 2A | 2 | Serotonin 2a (5-HT2a) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3356 | Drugs and targets |
| SLC5A2 | Sodium/glucose cotransporter 2 | 2 | Sodium/glucose cotransporter 2 inhibitor | Phase 3 | https://conductscience.org/library/genes/6524 | Drugs and targets |
| CHRNA4 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2/3 | https://conductscience.org/library/genes/1137 | Drugs and targets |
| CHRNB2 | Neuronal acetylcholine receptor; alpha4/beta2 | 1 | Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist | Phase 2/3 | https://conductscience.org/library/genes/1141 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 3 | https://conductscience.org/library/genes/56901 | Drugs and targets |
1 to 10 of 71
See all 71 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02044874 | A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation | Phase 2 | 603 | 2019-04-16 | Smoking Cessation | LORCASERIN HYDROCHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01866098 | Naltrexone for Antipsychotic-Induced Weight Gain | Not applicable | 144 | 2020-04-08 | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features | NALTREXONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02168660 | Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth | Phase 2 | 109 | 2019-12-09 | Obesity, Insulin Resistance, Vitamin D Deficiency | CHOLECALCIFEROL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02412631 | Addressing Post Cessation Weight Gain | Phase 2/3 | 84 | 2021-06-10 | Obesity, Smoking Cessation | LORCASERIN, VARENICLINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01825798 | Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD) | Phase 3 | 60 | 2018-02-22 | Overweight, Autism Spectrum Disorder | METFORMIN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00709202 | Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain | Phase 2 | 48 | 2019-01-25 | Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar I Disorder, Bipolar II, Bipolar NOS(Not Otherwise Specified), Psychotic Disorder Not Otherwise Specified, Autism Spectrum Disorder | BETAHISTINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00502216 | Naltrexone and Varenicline: Weight Gain and Tolerability in Cigarette Smokers | Phase 1/2 | 40 | 2010-09-21 | Smoking, Nicotine Dependence | NALTREXONE, VARENICLINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06317051 | Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART) | Phase 3 | 300 | HIV Infections, Weight Gain | DAPAGLIFLOZIN, EZETIMIBE, PITAVASTATIN, ROSUVASTATIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06323174 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise | Phase 3 | 189 | Type 2 Diabetes | CAGRILINTIDE, SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03877562 | The Effect of CORT118335 on Olanzapine-Induced Weight Gain | Phase 1 | 96 | Antipsychotic-induced Weight Gain | MIRICORILANT | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials8
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Varenicline Plus Placebo vs Varenicline Plus Lorcaserin: Smoking Abstinence | 13 of 44 | 8 of 40 | 84 | NCT02412631 | Trial comparisons |
| Varenicline Plus Placebo vs Varenicline Plus Lorcaserin: deaths from any cause | 0 of 44 | 0 of 40 | 84 | NCT02412631 | Trial comparisons |
| Varenicline Plus Placebo vs Varenicline Plus Lorcaserin: serious adverse events | 0 of 44 | 0 of 40 | 84 | NCT02412631 | Trial comparisons |
| Metformin vs Placebo Hydrochloride Oral Solution: serious adverse events | 0 of 28 | 1 of 32 | 60 | NCT01825798 | Trial comparisons |
| Varenicline + Naltrexone vs Varenicline + Placebo: Tolerability of the Combination of 25 mg Naltrexone and 2 mg Varenicline | 10 of 21 | 4 of 19 | 40 | NCT00502216 | Trial comparisons |
| Varenicline + Naltrexone vs Varenicline + Placebo: serious adverse events | 0 of 21 | 0 of 19 | 40 | NCT00502216 | Trial comparisons |
| Betahistine vs Placebo: deaths from any cause | 0 of 19 | 0 of 20 | 39 | NCT00709202 | Trial comparisons |
| Betahistine vs Placebo: serious adverse events | 0 of 19 | 0 of 20 | 39 | NCT00709202 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42251860 | DERIVED | 1 | PubMed |
| 42050587 | DERIVED | 1 | PubMed |
| 37142273 | DERIVED | 1 | PubMed |
| 36160639 | DERIVED | 1 | PubMed |
| 34611902 | DERIVED | 1 | PubMed |
| 30542300 | DERIVED | 1 | PubMed |
| 28942807 | DERIVED | 1 | PubMed |
| 27815511 | DERIVED | 1 | PubMed |
| 27556593 | DERIVED | 1 | PubMed |
| 24947583 | DERIVED | 1 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0004324
GET https://conductscience.org/api/diseases/v1/HP_0004324/drugs?page=2